Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Aβ immunization

Journal of Molecular Neuroscience

Volumn 17, Issue 2, 2001, Pages 259-267

  Schenk, D ^a   Games, D ^a   Seubert, P ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Beta secretase; Gamma secretase; Immunization

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; ENZYME INHIBITOR; GAMMA SECRETASE;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; CLINICAL FEATURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPOTHESIS; IMMUNIZATION; NEUROPATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES; ASPARTIC ENDOPEPTIDASES; BRAIN; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; HUMANS; IMMUNOTHERAPY; MICE;

EID: 0035169318     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:17:2:259     Document Type: Article

References (63)

1. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
2. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
3. Alzheimer's disease: Neurodevelopment converges with neurodegeneration
4. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene
5. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production
6. Mutant presenilins of Alzheimer's disease increase production of 42- residue amyloid beta-protein in both transfected cells and transgenic mice
7. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
8. Nonnuclear effects of the steroid hormone 1 alpha,25(OH) 2-vitamin D3: Analogs are able to functionally differentiate between nuclear and membrane receptors
9. Functional gammasecretase inhibitors reduce beta-amyloid peptide levels in brain
10. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1
11. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes
12. The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide
13. Cleavage of amyloid beta peptide during constitutive processing of its precursor
14. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1
15. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
16. Cholinesterase inhibitors stabilize Alzheimer disease
17. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
18. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
19. Treatment of Alzheimer's disease: Rationale and strategies
20. Cholinesterase inhibitors for Alzheimer's disease
21. Amyloid beta-peptide is produced by cultured cells during normal metabolism
22. New insights into the genetics of Alzheimer's disease
23. Alzheimer disease: The new agenda
24. Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism
25. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice
26. Zincinduced Alzheimer's Abetal-40 aggregation is mediated by conformational factors
27. Visualization of A beta 42(43) and A beta 40 in senile plaques with end- specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43)
28. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
29. A common enzyme connects notch signaling and Alzheimer's disease
30. Separation of presenilin function in amyloid beta-pep tide generation and endoproteolysis of Notch
31. The E280A presenilin 1 Alzheimer mutation produces increased Abeta 42 deposition and severe cerebellar pathology
32. Photoactivated gammasecretase inhibitors directed to the active site covalently label presenilin 1
33. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation
34. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease
35. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
36. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid
37. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene
38. Correlation between elevated levels of amyloid betapeptide in the brain and cognitive decline
39. Mild cognitive impairment: Clinical characterization and outcome
40. New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage
41. BACE knockout mice are healthy despite lacking the primary betasecretase activity in brain: Implications for Alzheimer's disease therapeutics
42. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
43. Beta-peptide immunization: A possible new treatment for Alzheimer disease
44. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease
45. The genetics and molecular pathology of Alzheimer's disease: Roles of amyloid and the presenilins
46. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide
47. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids
48. Purification and cloning of amyloid precursor protein beta-secretase from human brain
49. Beta-amyloid precursor protein cleavage by a membrane-bound protease
50. Function and dysfunction of the presenilins
51. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide
52. Ongoing trials in Alzheimer's disease
53. A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling
54. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
55. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants
56. Trials to slow progression and prevent disease onset
57. Frontotemporal lobar degeneration. An update on clinical, pathological and genetic findings
58. Beta-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE
59. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease
60. Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation
61. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity
62. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing
63. Beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes